strokes were the result of VZV (shingles) activation; cognitive issues; stroke; Booster; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 74 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 11Sep2021 15:15 (Lot number: FE3592) at the age of 74 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Diabetes mellitus" (unspecified if ongoing); "Penicillin allergy" (unspecified if ongoing). Concomitant medication(s) included: FLUZONE HIGH DOSE QUADRIVALENT, start date: 05Oct2021, stop date: 05Oct2021. Past drug history included: Metformin, reaction(s): "Allergy". Vaccination history included: Bnt162b2 (dose product = COVID 19, brand = Pfizer-BioNTech, lot number = EL9265, dose 2, vaccine location = right arm), administration date: 06Feb2021, when the patient was 74 years old, for COVID-19 immunisation, reaction(s): "Stroke", "VZV (shingles) activation", "cognitive issues", "pulmonary blood clots", "encephalitis"; Bnt162b2 (dose product = COVID 19, brand = Pfizer-BioNTech, lot number = EK9231, dose 1, vaccine location = right arm), administration date: 16Jan2021, when the patient was 74 years old, for COVID-19 immunisation. The following information was reported: CEREBROVASCULAR ACCIDENT (hospitalization, disability, life threatening) with onset 08Nov2021, outcome "not recovered", described as "stroke"; HERPES ZOSTER (hospitalization, disability, life threatening), outcome "not recovered", described as "strokes were the result of VZV (shingles) activation"; COGNITIVE DISORDER (hospitalization, disability, life threatening), outcome "not recovered", described as "cognitive issues"; IMMUNISATION (hospitalization, disability, life threatening) with onset 11Sep2021 15:15, outcome "unknown", described as "Booster". The events "stroke", "strokes were the result of vzv (shingles) activation" and "cognitive issues" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: investigation: (unspecified date) strokes were the result of vzv (shingles), notes: suggested that his strokes were the result of VZV (shingles) activation; sars-cov-2 test: (05Nov2021) negative, notes: Nasal Swab. Therapeutic measures were taken as a result of cerebrovascular accident, herpes zoster, cognitive disorder. Additional information: Other vaccine in four weeks included Fluzone Quad. The patient sustained a stroke on 04Jun2021 and a second stroke on 08Nov2021. Workup suggested that his strokes were the result of VZV (shingles) activation. He is still doing rehabilitation now and has cognitive issues. AE resulted in: doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care, hospitalization, life threatening illness (immediate risk of death from the event), and disability or permanent damage. AE treatment included acyclovir, immunoglobulins, steroids, and anticoag. No COVID prior to vaccination.; Sender's Comments: The events were considered as intercurrent conditions and unrelated to product bnt162b2 (BNT162B2). This case will be reassessed upon receipt of follow-up information.,Linked Report(s) : US-PFIZER INC-202101850694 same patient and product, different dose and events